Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics (Nasdaq: HOWL) announced three poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5-9, 2025, in National Harbor, Maryland.
Posters cover: sequential administration of IL-2 and IL-12 INDUKINE molecules (Abstract 861) on Nov 7; development of masked conditional T cell engagers (Abstract 964) on Nov 8; and pharmacokinetics of IL-2 INDUKINE prodrug WTX-124 (Abstract 862) on Nov 8. All presentations in Poster Hall (Exhibit Halls A and B1).
Werewolf Therapeutics (Nasdaq: HOWL) ha annunciato tre poster al SITC 40th Annual Meeting, dal 5 al 9 novembre 2025, a National Harbor, Maryland.
I poster riguardano: somministrazione sequenziale di IL-2 e IL-12 INDUKINE molecole (Abstract 861) il 7 novembre; sviluppo di ingaggiatori T cellulari mascherati condizionali (Abstract 964) l'8 novembre; e farmacocinetica del prodrug IL-2 INDUKINE WTX-124 (Abstract 862) l'8 novembre. Tutte le presentazioni si svolgono nella Poster Hall (Exhibit Halls A e B1).
Werewolf Therapeutics (Nasdaq: HOWL) anunció tres pósters en la SITC 40th Annual Meeting, del 5 al 9 de noviembre de 2025, en National Harbor, Maryland.
Los pósteres cubren: administración secuencial de moléculas IL-2 e IL-12 INDUKINE (Abstract 861) el 7 de noviembre; desarrollo de engagers de células T enmascarados condicionales (Abstract 964) el 8 de noviembre; y la farmacocinética del profármaco IL-2 INDUKINE WTX-124 (Abstract 862) el 8 de noviembre. Todas las presentaciones en Poster Hall (Exhibit Halls A y B1).
Werewolf Therapeutics (Nasdaq: HOWL)는 2025년 11월 5일부터 9일까지 메릴랜드주 내셔널 하버에서 열리는 SITC 40th Annual Meeting에서 포스터 3편을 발표한다고 발표했습니다.
포스터 주제: IL-2 및 IL-12 INDUKINE 분자의 순차적 투여(Abstract 861)는 11월 7일; 마스킹된 조건부 T 세포 엔게저(Abstract 964) 11월 8일; IL-2 INDUKINE 프로드러그 WTX-124의 약물동태학(Abstract 862) 11월 8일. 모든 발표는 포스터 홀(전시 홀 A 및 B1)에서 진행됩니다.
Werewolf Therapeutics (Nasdaq : HOWL) a annoncé trois posters lors de la SITC 40th Annual Meeting, du 5 au 9 novembre 2025, à National Harbor, Maryland.
Les posters portent sur : l'administration séquentielle de molécules IL-2 et IL-12 INDUKINE (Abstract 861) le 7 novembre ; le développement d'ENGAGERS T cellulaires masqués conditionnels (Abstract 964) le 8 novembre ; et la pharmacocinétique du prodrug IL-2 INDUKINE WTX-124 (Abstract 862) le 8 novembre. Toutes les présentations auront lieu dans le Poster Hall (Exhibit Halls A et B1).
Werewolf Therapeutics (Nasdaq: HOWL) kündigte drei Poster auf der SITC 40th Annual Meeting vom 5. bis 9. November 2025 in National Harbor, Maryland, an.
Die Poster decken ab: Sequenzielle Verabreichung von IL-2 und IL-12 INDUKINE-Molekülen (Abstract 861) am 7. November; Entwicklung von maskierten bedingten T-Zell-Engagern (Abstract 964) am 8. November; und Pharmakokinetik des IL-2 INDUKINE Prodrug WTX-124 (Abstract 862) am 8. November. Alle Präsentationen finden im Poster Hall statt (Exhibit Halls A und B1).
Werewolf Therapeutics (Nasdaq: HOWL) أعلنت عن ثلاث عروض ملصقة في الاجتماع السنوي الأربعين لجمعية SITC، في الفترة من 5 إلى 9 نوفمبر 2025، في ناشيونال هاربور، ميريلاند.
تغطي الملصقات: الإدارة المتتابعة لجزيئات IL-2 و IL-12 INDUKINE (الملخص 861) في 7 نوفمبر؛ تطوير محولات خلايا T مشروطة مع قناع (الملخص 964) في 8 نوفمبر؛ ودوائية IL-2 INDUKINE پرو-دوغ WTX-124 (الملخص 862) في 8 نوفمبر. جميع العروض في قاعة الملصقات (صالات العرض A و B1).
Werewolf Therapeutics (Nasdaq: HOWL)宣布将在 SITC 第40届年会（2025年11月5日至9日，马里兰州 National Harbor）上展示三份海报。
海报内容包括：IL-2 与 IL-12 INDUKINE 分子的序贯给药（摘要861）在11月7日；罩盖的条件性T细胞招募剂的开发（摘要964）在11月8日；以及 IL-2 INDUKINE 前药 WTX-124 的药代动力学（摘要862）在11月8日。所有演讲均在海报厅举行（展馆 A 与 B1）。
- None.
- None.
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.
Details for the poster presentations are as follows:
Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity
Abstract Number: 861
Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.
Location: Poster Hall (Exhibit Halls A and B1)
Title: Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity
Abstract Number: 964
Session Date and Time: Nov. 8, 2025; 12:15-1:45, 5:10-6:35 p.m.
Location: Poster Hall (Exhibit Halls A and B1)
Title: Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation
Abstract Number: 862
Session Date and Time: Nov. 8, 2025; 12:15-1:45, 5:10- 6:35 p.m.
Location: Poster Hall (Exhibit Halls A and B1)
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple solid tumor types as a single agent. Werewolf is leveraging positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™, INDUCER™, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
When will Werewolf Therapeutics (HOWL) present at SITC 2025?
What topics will HOWL cover in its SITC 2025 posters?
Where are Werewolf’s posters located at SITC 2025?
What are the abstract numbers for Werewolf’s SITC 2025 posters?
Does the press release report clinical or financial results for HOWL?
How can investors view Werewolf’s SITC 2025 presentations for HOWL?
